In a small study, Yale researchers have found "differences in immune profiles" among those who have rare reaction to the ...

I could discuss risks and benefits in a more sophisticated way if I better understood a patient’s risk versus their ...

Yale researchers have found clues as to why certain people experience adverse health effects after the COVID-19 vaccine, which they have dubbed “post-vaccination syndrome." ...

FDA's reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent ...

These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...

The authors compared outcomes among adults just under 70 years who were not prescribed Paxlovid to those who were given the ...

Bay Area News Group: Berkeley Man Sues Kaiser Permanente, Accuses Medical Assistant Of Sexual Assault During Cancer Surgery A Kaiser Permanente patient filed a lawsuit last week against the ...